-
2 weeks ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
OpinionVideoJune 12, 2025Author(s):,Panelists discuss how recent advancements in NMIBC treatment, including the approval of nadofaragene firadenovec, pembrolizumab, and intravesical therapies like TAR-200, have reshaped care for BCG-unresponsive patients, with promising developments and ongoing trials at AUA 2025 paving the way for more personalized and effective treatment strategies in the future.
-
2 weeks ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
OpinionVideoJune 12, 2025Author(s):,Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access barriers, ensuring that NMIBC patients receive timely access to novel treatments like nadofaragene firadenovec and pembrolizumab.
-
2 weeks ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
OpinionVideoJune 12, 2025Author(s):,Panelists discuss how overcoming challenges such as cost, insurance coverage, regulatory hurdles, patient selection, and the need for education is crucial for improving access to novel therapies like nadofaragene firadenovec and pembrolizumab, ultimately enhancing outcomes for NMIBC patients.
-
3 weeks ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how recent trials, including KEYNOTE-057, QUILT-3.032, and CORE-001, highlight the promising efficacy, durability, and manageable safety profiles of novel treatments like pembrolizumab, nogapendekin alfa inbakicept, and nadofaragene firadenovec, while also exploring the potential of combination therapies and novel intravesical options like TAR-200 and UGN-102 for improving outcomes in non–muscle-invasive bladder cancer (NMIBC).
-
3 weeks ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how the ongoing ABLE-32 and ABLE-41 trials are exploring the efficacy and safety of nadofaragene firadenovec in different NMIBC patient populations, with ABLE-32 focusing on intermediate-risk patients and ABLE-41 examining real-world effectiveness and safety. The ongoing clinical trials investigating nadofaragene firadenovec include the ABLE-32 and ABLE-41 trials, each focusing on different aspects of its use in treating non-muscle invasive bladder cancer (NMIBC).
-
1 month ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how real-world data from a recent Mayo Clinic study confirms the promising efficacy and favorable safety profile of nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting high cystectomy-free and overall survival rates, with longer follow-up needed to assess response durability.
-
1 month ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how nogapendekin alfa, an intravesical immunotherapy that stimulates a localized immune response, combined with BCG therapy, provides a novel dual approach for treating BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), targeting both local and systemic immune responses.
-
1 month ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how pembrolizumab, a PD-1 inhibitor, offers a systemic immunotherapy option for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) by enhancing the immune system’s ability to target cancer cells, with intravenous administration and careful monitoring for immune-related adverse effects.
-
1 month ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how recently FDA-approved therapies, including nadofaragene firadenovec, gemcitabine, and docetaxel, offer alternative treatment options for BCG-unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC), each with distinct mechanisms and administration methods. Physician Summary:Three recently FDA-approved agents for the treatment of high-risk, BCG-unresponsive NMIBC provide alternative options for patients who do not respond to standard BCG therapy.
-
1 month ago | 
urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger
Author(s):,Panelists discuss how maintenance BCG therapy and vigilant surveillance are essential for sustaining disease control in NMIBC patients, with treatment schedules and monitoring tailored to individual risk and tolerance. Physician Summary:For patients with initially responsive NMIBC, maintenance therapy is a cornerstone of ongoing disease control, particularly in those with intermediate- or high-risk features.
